Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00130364
- Locations
- 🇺🇸
This study is not being conducted in the United States, Novartis Pharmaceuticals, New Jersey, United States
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
- Conditions
- Asthma
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 155
- Registration Number
- NCT00130351
- Locations
- 🇺🇸
Allergy and Asthma Specialists Medical Group and Research Ct, Huntington Beach, California, United States
🇺🇸Allergy and Asthma Medical Group & Research Center, San Diego, California, United States
🇺🇸Allergy & Asthma Associates of Santa Clara Res. Center, San Jose, California, United States
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
- Conditions
- Genital Herpes
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00129818
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸IU Center for Clinical STD Research, Indianapolis, Indiana, United States
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 6
- Registration Number
- NCT00129831
- Locations
- 🇺🇸
Radiant Research, Boise, Idaho, United States
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
- Conditions
- Hepatitis B
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00128544
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 440
- Registration Number
- NCT00128245
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
- Conditions
- Acromegaly
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 100
- Registration Number
- NCT00128232
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
- Conditions
- Urinary Incontinence
- Interventions
- Behavioral: Behavioral therapy
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2008-01-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 395
- Registration Number
- NCT00127270
- Locations
- 🇺🇸
Alabama Research Center, Birmingham, Alabama, United States
🇺🇸Quality of Life Medical & Research, Tucson, Arizona, United States
🇺🇸UCLA - Urology Sciences Research Foundation, Culver City, California, United States
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 98
- Registration Number
- NCT00125346
- Locations
- 🇲🇽
For information on a site near you, call 1-800-244-7668 Option "2", Tijuana, Mexico
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 218
- Registration Number
- NCT00125125
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States